{"data":{"id":"us-ca/bpc-22949.51","jurisdiction":"us-ca","citation":"BPC § 22949.51","heading":"","body":"For purposes of this chapter, the following definitions apply:\n(a) “Gene therapy” refers to the administration of genetic material to modify or manipulate the expression of a gene product, or to alter the biological properties of living cells, for therapeutic use.\n(b) “Gene therapy kit” refers to a product that is sold as a collection of materials for the purpose of facilitating gene therapy experiments, including, but not limited to, a system for the targeted cutting of DNA molecules, such as type II clustered regularly interspaced short palindromic repeats (CRISPR), associated proteins (CRISPR-Cas) systems, including CRISPR-Cas9, as described in Regents of University of California v. Broad Institute, Inc. (2018) 903 F.3d 1286.","path":["Business and Professions Code - BPC","DIVISION 8. SPECIAL BUSINESS REGULATIONS [18400. - 22949.92.2.]","CHAPTER 37. Gene Therapy Kits: Notice [22949.50. - 22949.51.]"],"source_url":"https://downloads.leginfo.legislature.ca.gov/pubinfo_2025.zip","current_through":"2026-09-13","vintage":"","retrieved_at":"2026-09-14T05:56:33Z","sha256":"64923a3f61b3a88368433fefd1224b8eab6b95ee4a0ffe00f8eb4542bbd053ab","source_id":"us-ca","stale":false,"prev":"us-ca/bpc-22949.50","next":"us-ca/bpc-22949.60"},"notice":"GroundRules: Original legal text. Not legal advice."}